Michael Shleifer

Vaccination biotech Vaxxas raises $49 million Series D, cuts C-suite amid broader layoffs

Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.

Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily

Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology

Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.